| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | C17L |
| Uniprot No | P33815 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-372aa |
| 氨基酸序列 | MWPFTSAPAGAKCRLVETLPENMDFRSDHLTTFECFNEIITLAKKYIYIASFCCNPLSTTRGALIFDKLKEASEKGIKIIVLLDERGKRNLGELQSHCPDINFITVNIDKKNNVGLLLGCFWVSDDERCYVGNASFTGGSIHTIKTLGVYSDYPPLATDLRRRFDTFKAFNSVKNSWLNLYSSACCLPVSTAYHIKNPIGGVFFTDSPEHLLGYSRDLDTDVVIDKLRSAKTSIDIEHLAIVPTTRVDGNSYYWPDIYNSIIEAAINRGVKIRLLVGNWDKNDVYSMATAESLDALCVQNDLSVKVFTIQNNTKLLIVDDEYVHITSANFDGTHYQNHGFVSFNSIDKQLVSEAKKIFERDWVSSHSKSLKI |
| 预测分子量 | 49.4 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于C17L重组蛋白的3篇参考文献示例(注：以下内容为虚构，仅用于示例用途)：
---
1. **文献名称**：*The Vaccinia Virus C17L Protein Inhibits Type I Interferon Signaling by Binding to the IFN-α/β Receptor*
**作者**：Smith, J. et al.
**摘要**：本研究通过体外重组表达了痘苗病毒C17L蛋白，证实其直接结合宿主IFN-α/β受体，阻断下游STAT信号通路，抑制I型干扰素的抗病毒作用，为痘病毒免疫逃逸机制提供了新证据。
2. **文献名称**：*Crystal Structure of the Vaccinia C17L Protein Reveals a Novel Fold for Immune Evasion*
**作者**：Li, X. & Chen, W.
**摘要**：首次解析了C17L重组蛋白的晶体结构(分辨率2.8Å)，发现其独特的β-折叠结构域与宿主免疫蛋白互作，揭示了痘病毒通过结构模拟干扰先天免疫应答的分子机制。
3. **文献名称**：*Expression and Functional Analysis of Recombinant C17L in a Mouse Model of Viral Infection*
**作者**：García, M. et al.
**摘要**：利用哺乳动物表达系统制备C17L重组蛋白，动物实验表明其显著增强痘苗病毒的致病性，敲除C17L后病毒诱导的炎症反应减弱，证实其在体内调控宿主免疫的关键作用。
---
**备注**：实际研究中，C17L相关文献可能集中于痘病毒家族(如牛痘病毒、天花病毒)的免疫调节蛋白研究。建议通过PubMed或Google Scholar检索“Vaccinia C17L”或“Poxvirus C17 homolog”获取真实文献。
C17L recombinant protein is derived from the C17L gene encoded by certain orthopoxviruses, including vaccinia virus (VACV) and variola virus (VARV). This protein belongs to the poxviral immune evasion family, characterized by its role in modulating host immune responses. The C17L protein is a secreted, highly conserved glycoprotein with a molecular weight of approximately 25–30 kDa. It features a conserved N-terminal domain and a C-terminal chemokine-binding domain, enabling interaction with host chemokines and their receptors.
Functionally, C17L acts as a potent antagonist of host chemokine signaling. It binds CC-class chemokines (e.g., CCL2. CCL5) and blocks their interaction with cellular receptors such as CCR1 and CCR5. thereby inhibiting leukocyte recruitment to infection sites. This immunosuppressive activity aids viral immune evasion, enhancing viral replication and spread. Studies in VACV models show that C17L deletion attenuates viral pathogenesis, underscoring its importance in virulence.
Recombinant C17L is typically produced in heterologous expression systems (e.g., E. coli or mammalian cells) for research applications. Its purified form facilitates structural studies, drug screening, and mechanistic investigations into poxviral immune evasion. Additionally, it serves as a tool to study chemokine-receptor interactions in inflammatory diseases. In vaccine development, understanding C17L’s role informs the design of attenuated viral vectors with optimized safety profiles.
Recent interest in C17L also stems from its potential as a therapeutic target or immunomodulatory agent. Its ability to suppress chemokine-driven inflammation suggests applications in autoimmune or hyperinflammatory disorders. However, further studies are needed to evaluate its efficacy and safety in clinical contexts. Overall, C17L recombinant protein represents a critical molecule for probing host-pathogen interactions and developing antiviral or immunotherapeutic strategies.
×
